Clovis Oncology (NASDAQ:CLVSQ – Get Rating) is one of 981 public companies in the "Pharmaceutical preparations" industry, but how does it weigh in compared to its competitors? We will compare Clovis Oncology to related businesses based on the strength of its valuation, institutional ownership, earnings, dividends, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a summary of current recommendations for Clovis Oncology and its competitors, as provided by MarketBeat.

As a group, "Pharmaceutical preparations" companies have a potential upside of 120.84%. Given Clovis Oncology's competitors higher possible upside, analysts clearly believe Clovis Oncology has less favorable growth aspects than its competitors.

Risk and Volatility

Clovis Oncology has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Clovis Oncology's competitors have a beta of 0.90, meaning that their average share price is 10% less volatile than the S&P 500.

Profitability

This table compares Clovis Oncology and its competitors' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Clovis Oncology and its competitors top-line revenue, earnings per share (EPS) and valuation.

Clovis Oncology's competitors have higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

24.5% of Clovis Oncology shares are owned by institutional investors. Comparatively, 40.7% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 4.4% of Clovis Oncology shares are owned by company insiders. Comparatively, 15.7% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Clovis Oncology competitors beat Clovis Oncology on 6 of the 10 factors compared.

About Clovis Oncology

(Get Rating)

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.